Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 H3N2 Infection Overview 10 Therapeutics Development 11 Pipeline Products for H3N2 Infection - Overview 11 Pipeline Products for H3N2 Infection - Comparative Analysis 12 H3N2 Infection - Therapeutics under Development by Companies 13 H3N2 Infection - Therapeutics under Investigation by Universities/Institutes 15 H3N2 Infection - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 H3N2 Infection - Products under Development by Companies 19 H3N2 Infection - Products under Investigation by Universities/Institutes 21 H3N2 Infection - Companies Involved in Therapeutics Development 22 AIMM Therapeutics B.V. 22 Aphios Corporation 23 Crucell N.V. 24 CSL Limited 25 Glide Pharmaceutical Technologies Limited 26 ILiAD Biotechnologies, LLC 27 Inovio Pharmaceuticals, Inc. 28 Johnson & Johnson 29 Medicago Inc. 30 MedImmune, LLC 31 Mucosis B.V. 32 NanoViricides, Inc. 33 Novavax, Inc. 34 OPKO Health, Inc. 35 Sarepta Therapeutics, Inc. 36 Takeda Pharmaceutical Company Limited 37 Visterra, Inc. 38 Zydus Cadila Healthcare Limited 39 H3N2 Infection - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Combination Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 APP-0205 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 APP-309 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Aspidasept - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 C-05 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 CR-8020 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CR-9114 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 FluGEM - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Gamma-Flu - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 influenza [strain A/H3N2] vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 influenza [strain A/H3N2] vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 JNJ-872 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 NVINF-1 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 NVINF-2 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 pertussis [strain BPZE1] vaccine - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 PNSIA-28 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 radavirsen - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules for RSV and Influenza A Infections - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 TXB-248 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 VIS-410 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 H3N2 Infection - Recent Pipeline Updates 90 H3N2 Infection - Dormant Projects 103 H3N2 Infection - Product Development Milestones 104 Featured News & Press Releases 104 Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 104 Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 104 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107

List of Tables Number of Products under Development for H3N2 Infection, H1 2016 11 Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 H3N2 Infection - Pipeline by AIMM Therapeutics B.V., H1 2016 22 H3N2 Infection - Pipeline by Aphios Corporation, H1 2016 23 H3N2 Infection - Pipeline by Crucell N.V., H1 2016 24 H3N2 Infection - Pipeline by CSL Limited, H1 2016 25 H3N2 Infection - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 26 H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 27 H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 28 H3N2 Infection - Pipeline by Johnson & Johnson, H1 2016 29 H3N2 Infection - Pipeline by Medicago Inc., H1 2016 30 H3N2 Infection - Pipeline by MedImmune, LLC, H1 2016 31 H3N2 Infection - Pipeline by Mucosis B.V., H1 2016 32 H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2016 33 H3N2 Infection - Pipeline by Novavax, Inc., H1 2016 34 H3N2 Infection - Pipeline by OPKO Health, Inc., H1 2016 35 H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016 36 H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 37 H3N2 Infection - Pipeline by Visterra, Inc., H1 2016 38 H3N2 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 39 Assessment by Monotherapy Products, H1 2016 40 Assessment by Combination Products, H1 2016 41 Number of Products by Stage and Target, H1 2016 43 Number of Products by Stage and Mechanism of Action, H1 2016 45 Number of Products by Stage and Route of Administration, H1 2016 47 Number of Products by Stage and Molecule Type, H1 2016 49 H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2016 90 H3N2 Infection - Dormant Projects, H1 2016 103 List of Figures Number of Products under Development for H3N2 Infection, H1 2016 11 Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 40 Assessment by Combination Products, H1 2016 41 Number of Products by Targets, H1 2016 42 Number of Products by Stage and Targets, H1 2016 42 Number of Products by Mechanism of Actions, H1 2016 44 Number of Products by Stage and Mechanism of Actions, H1 2016 44 Number of Products by Top 10 Routes of Administration, H1 2016 46 Number of Products by Stage and Routes of Administration, H1 2016 46 Number of Products by Molecule Types, H1 2016 48 Number of Products by Stage and Molecule Types, H1 2016 48

AIMM Therapeutics B.V. Aphios Corporation Crucell N.V. CSL Limited Glide Pharmaceutical Technologies Limited ILiAD Biotechnologies, LLC Inovio Pharmaceuticals, Inc. Johnson & Johnson Medicago Inc. MedImmune, LLC Mucosis B.V. NanoViricides, Inc. Novavax, Inc. OPKO Health, Inc. Sarepta Therapeutics, Inc. Takeda Pharmaceutical Company Limited Visterra, Inc. Zydus Cadila Healthcare Limited